170 related articles for article (PubMed ID: 35795129)
1. Long-term survival of a patient with refractory advanced adrenocortical carcinoma after combination chemotherapy with paclitaxel and carboplatin plus mitotane.
Kobayakawa Y; Hamamoto S; Kamisawa H; Okada S; Taguchi K; Naiki T; Okada A; Tozawa K; Yasui T
IJU Case Rep; 2022 Jul; 5(4):288-292. PubMed ID: 35795129
[TBL] [Abstract][Full Text] [Related]
2. Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second-line chemotherapy.
Yamamoto A; Nakai Y; Oka T; Kanaki T; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Nishimura K
IJU Case Rep; 2020 Nov; 3(6):270-273. PubMed ID: 33163922
[TBL] [Abstract][Full Text] [Related]
3. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
[TBL] [Abstract][Full Text] [Related]
5. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
6. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
Sasaki S
Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
[TBL] [Abstract][Full Text] [Related]
7. Long-term partial response in a patient with liver metastasis of primary adrenocortical carcinoma with adjuvant mitotane plus transcatheter arterial chemoembolization and microwave ablation: a case report.
Deng J; Wei L; Fan Q; Wu Z; Ji Z
Front Oncol; 2023; 13():1157740. PubMed ID: 37313469
[TBL] [Abstract][Full Text] [Related]
8. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
9. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
11. Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma.
Weng Y; Wang L; Wang XY; Fan XX; Yan L; Li ZH; Zhang SL
Front Endocrinol (Lausanne); 2023; 14():1115893. PubMed ID: 37745701
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
13. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
14. Durable response to pembrolizumab in microsatellite instability-high advanced adrenocortical carcinoma.
Senda M; Hashimoto K; Shindo T; Kobayashi K; Tanaka T; Masumori N
IJU Case Rep; 2023 Nov; 6(6):382-385. PubMed ID: 37928286
[TBL] [Abstract][Full Text] [Related]
15. Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma.
Ohmoto A; Shigematsu Y; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Komai Y; Numao N; Yuasa T; Yonese J; Tomomatsu J; Inamura K; Takahashi S
Endocr J; 2021 Dec; 68(12):1383-1390. PubMed ID: 34176818
[TBL] [Abstract][Full Text] [Related]
16. Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor.
Oddie PD; Albert BB; Hofman PL; Jefferies C; Laughton S; Carter PJ
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 30159150
[TBL] [Abstract][Full Text] [Related]
17. Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy.
Chalasani S; Vats HS; Banerjee TK; McKenzie AK
Clin Med Res; 2009 Jun; 7(1-2):48-51. PubMed ID: 19574489
[TBL] [Abstract][Full Text] [Related]
18. Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane.
Sperone P; Berruti A; Gorzegno G; Paccotti P; Terzolo M; Porpiglia F; Angeli A; Dogliotti L
J Endocrinol Invest; 2006 Jun; 29(6):560-2. PubMed ID: 16840836
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival in recurrent adrenocortical cancer.
Shuayb M; Das A; Uddin MN
BMJ Support Palliat Care; 2019 Mar; 9(1):47-50. PubMed ID: 29903850
[TBL] [Abstract][Full Text] [Related]
20. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
